The P2Y12 inhibitor was initially used for its platelet anti-aggregatory action to block thrombosis of the recanalized coronary artery or deployed stent. It is now recognized that these agents also offer potent cardioprotection against a reperfusion injury that occurs in the first minutes of ...
The combination of aspirin and a P2Y12receptor inhibitor is the cornerstone of treatment in patients with acute coronary syndromes (ACS) and in those undergoing percutaneous coronary intervention (PCI). At the present time, three differe... L De Luca,P Capranzano,G Patti,... - 《American He...
this choice brings with it the problem of deciding which antithrombotic to use for which patient. Also, which antithrombotic regimen is best in the first 12 months after ACS or PCI and what is the optimal strategy
Rather than being an inert barrier that merely regulates the exchange of solutes between circulating blood and surrounding tissues, the endothelial monolayer is critical to maintain cardiovascular homeostasis, by finely tuning a wealth of critical processes, including adjustment of vascular tone according ...
Want to thank TFD for its existence?Tell a friend about us, add a link to this page, or visitthe webmaster's page for free fun content. Link to this page: Facebook Twitter Acronyms browser? ▲ DAPOS DApp DAPP-BQ DAPPA DAPPAF
What is the optimal time for DAPT initiation: P2Y12 inhibitor administration in the ambulance, emergency room or cathlab?M. Möckel
What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndromedoi:10.1177/1074248419882923Michael V CohenJames M DowneyJ Cardiovasc Pharmacol Ther
The optimal time to start and the duration of dual antiplatelet therapy (DAPT; aspirin plus a P2Y12 inhibitor) have not been clearly established. Recent clinical trials have provided important new information allowing for evidence-based decisions regarding timing of initiation and duration of DAPT. ...
CLOPIDOGREL IS THE MOST WIDELY PRESCRIBED PLATElet P2Y12 receptor inhibitor and is recommended, in addition to aspirin, for prevention of atherothrombotic recurrences inpatientswithacutecoronary syndromes (ACS) and for those undergoing percutaneous coronary interventions (PCI). Despite the proven efficacy ...
Aspirin is the foundation antiplatelet agent. New P2Y12 receptor inhibitors (prasugrel and ticagrelor) have clear benefits compared with clopidogrel for dual antiplatelet therapy, and cangrelor or vorapaxar, a thrombin receptor inhibitor, may be of value in specific settings. Anticoagulation uses 1 of ...